CALEY BOGATZ: Open Payments
NPI 1699377515 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,174 in 71 payments from 20 companies in 2025. Trend: 2023 $460 · 2024 $432 · 2025 $1,174
Food & beverage: $1,174
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $491 |
| PFIZER INC. | 10 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Janssen Pharmaceuticals, Inc | 1 | $42 |
| Novo Nordisk Inc | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Boston Scientific Corporation | 1 | $22 |
Products named: VRAYLAR, UBRELVY, QULIPTA, CAPLYTA, REXULTI, NURTEC ODT, VYNDAMAX, SPRAVATO.
Industry payments across NE — which companies pay providers there.
